NASDAQ:ELVN Enliven Therapeutics (ELVN) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free ELVN Stock Alerts $17.18 +0.40 (+2.38%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$16.16▼$17.5250-Day Range$11.54▼$23.8252-Week Range$9.80▼$26.00Volume148,934 shsAverage Volume500,130 shsMarket Capitalization$804.20 millionP/E RatioN/ADividend YieldN/APrice Target$34.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Enliven Therapeutics alerts: Email Address Enliven Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside97.9% Upside$34.00 Price TargetShort InterestBearish18.33% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.26Based on 5 Articles This WeekInsider TradingSelling Shares$12.95 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.16) to ($2.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.77 out of 5 starsMedical Sector622nd out of 916 stocksBiotechnology Industry12th out of 24 stocks 3.5 Analyst's Opinion Consensus RatingEnliven Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageEnliven Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted18.33% of the float of Enliven Therapeutics has been sold short.Short Interest Ratio / Days to CoverEnliven Therapeutics has a short interest ratio ("days to cover") of 18.7, which indicates bearish sentiment.Change versus previous monthShort interest in Enliven Therapeutics has recently increased by 9.69%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEnliven Therapeutics does not currently pay a dividend.Dividend GrowthEnliven Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ELVN. Previous Next 2.4 News and Social Media Coverage News SentimentEnliven Therapeutics has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Enliven Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows5 people have added Enliven Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enliven Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,951,723.00 in company stock.Percentage Held by Insiders45.80% of the stock of Enliven Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.08% of the stock of Enliven Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Enliven Therapeutics are expected to decrease in the coming year, from ($2.16) to ($2.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enliven Therapeutics is -7.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enliven Therapeutics is -7.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnliven Therapeutics has a P/B Ratio of 2.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIIf you have $2,500 bucks… check this out This computer whiz has been averaging 234% per year with an undefeated strategy he calls… The “Income Glitch” And he’s been making out like a bandit with a 100% success rate on over 64 trade opportunities! Click here to unlock the Income Glitch training workshop for free. About Enliven Therapeutics Stock (NASDAQ:ELVN)Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Read More ELVN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ELVN Stock News HeadlinesApril 16, 2024 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman Sells 1,270 SharesApril 16, 2024 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells $25,387.30 in StockApril 28, 2024 | WealthPress (Ad)It’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. April 13, 2024 | insidertrades.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells 53,400 Shares of StockApril 11, 2024 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 4,875 SharesApril 9, 2024 | insidertrades.comRahul D. Ballal Sells 3,485 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockApril 4, 2024 | insidertrades.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells 3,237 Shares of StockMarch 31, 2024 | insidertrades.comBenjamin Hohl Sells 3,250 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockApril 28, 2024 | WealthPress (Ad)It’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. March 28, 2024 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz Sells 12,000 SharesApril 28, 2024 | nasdaq.comCommit To Purchase Enliven Therapeutics At $10, Earn 11.2% Annualized Using OptionsApril 28, 2024 | americanbankingnews.comFinancial Survey: Enliven Therapeutics (NASDAQ:ELVN) vs. Processa Pharmaceuticals (NASDAQ:PCSA)April 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Apellis Pharmaceuticals Amid Positive Outlook and Growth PotentialApril 26, 2024 | markets.businessinsider.comBuy Rating Affirmed: Enliven Therapeutics’ ELVN-001 Shows Market Potential and Efficacy in Resistant PatientsApril 21, 2024 | americanbankingnews.comEnliven Therapeutics (NASDAQ:ELVN) Sees Strong Trading VolumeApril 19, 2024 | finance.yahoo.comMasterCraft Boat, SentinelOne, and More Stocks See Action From Activist InvestorsApril 18, 2024 | msn.comEnliven Therapeutics files to sell 6.43M shares for holdersApril 18, 2024 | americanbankingnews.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells $751,200.00 in StockApril 17, 2024 | msn.comEnliven Therapeutics (ELVN) Price Target Increased by 10.75% to 35.02April 16, 2024 | investing.comEnliven Therapeutics CMO sells $501k in company stockApril 12, 2024 | investing.comEnliven reports promising Phase 1 data for leukemia drugApril 11, 2024 | markets.businessinsider.comStrong Buy Rating for Enliven Therapeutics’ ELVN-001 Following Outstanding Phase 1 Results and Market PotentialApril 11, 2024 | finance.yahoo.comEnliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead ProgramApril 11, 2024 | msn.comEnliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On ThursdayApril 11, 2024 | marketwatch.comEnliven Therapeutics Shares Hit 52-Week High After Positive Proof of Concept Data for Blood Cancer DrugApril 11, 2024 | proactiveinvestors.comEnliven Therapeutics shares rise on promising preliminary data for blood cancer drugApril 11, 2024 | globenewswire.comEnliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid LeukemiaSee More Headlines Receive ELVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enliven Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today4/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:ELVN CUSIPN/A CIK1672619 Webimaratx.com Phone617-927-9989FaxN/AEmployees46Year FoundedN/APrice Target and Rating Average Stock Price Target$34.00 High Stock Price Target$34.00 Low Stock Price Target$34.00 Potential Upside/Downside+97.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,580,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-26.56% Return on Assets-25.18% Debt Debt-to-Equity RatioN/A Current Ratio10.28 Quick Ratio10.28 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.97 per share Price / Book2.88Miscellaneous Outstanding Shares46,810,000Free Float25,368,000Market Cap$804.20 million OptionableOptionable Beta1.06 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Samuel S. Kintz M.B.A. (Age 38)Co-Founder, CEO, Secretary & Director Comp: $597kDr. Helen Louise Collins M.D. (Age 61)Chief Medical Officer Comp: $558kDr. Joseph P. Lyssikatos Ph.D. (Age 59)Co-Founder, Chief Scientific Officer & Directors Dr. Galya D. Blachman Esq. (Age 47)Ph.D., Chief Legal Officer & Head of Business Development Key CompetitorsARS PharmaceuticalsNASDAQ:SPRYTango TherapeuticsNASDAQ:TNGXArcutis BiotherapeuticsNASDAQ:ARQTSage TherapeuticsNASDAQ:SAGE89bioNASDAQ:ETNBView All CompetitorsInsiders & InstitutionsRichard A HeymanSold 1,270 sharesTotal: $25,387.30 ($19.99/share)Rahul D BallalSold 53,400 sharesTotal: $1.28 M ($23.95/share)Samuel KintzSold 47,709 sharesTotal: $1.19 M ($25.04/share)Joseph P. LyssikatosSold 30,000 sharesTotal: $751,200.00 ($25.04/share)Anish PatelSold 17,500 sharesTotal: $438,025.00 ($25.03/share)View All Insider TransactionsView All Institutional Transactions ELVN Stock Analysis - Frequently Asked Questions Should I buy or sell Enliven Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enliven Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ELVN shares. View ELVN analyst ratings or view top-rated stocks. What is Enliven Therapeutics' stock price target for 2024? 1 equities research analysts have issued 1-year price targets for Enliven Therapeutics' stock. Their ELVN share price targets range from $34.00 to $34.00. On average, they expect the company's share price to reach $34.00 in the next year. This suggests a possible upside of 97.9% from the stock's current price. View analysts price targets for ELVN or view top-rated stocks among Wall Street analysts. How have ELVN shares performed in 2024? Enliven Therapeutics' stock was trading at $13.84 at the beginning of 2024. Since then, ELVN shares have increased by 24.1% and is now trading at $17.18. View the best growth stocks for 2024 here. Are investors shorting Enliven Therapeutics? Enliven Therapeutics saw a increase in short interest in April. As of April 15th, there was short interest totaling 4,640,000 shares, an increase of 9.7% from the March 31st total of 4,230,000 shares. Based on an average daily volume of 247,800 shares, the days-to-cover ratio is presently 18.7 days. Currently, 18.3% of the company's stock are sold short. View Enliven Therapeutics' Short Interest. When is Enliven Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ELVN earnings forecast. How were Enliven Therapeutics' earnings last quarter? Enliven Therapeutics, Inc. (NASDAQ:ELVN) released its quarterly earnings data on Thursday, March, 14th. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.56) by $0.09. What ETFs hold Enliven Therapeutics' stock? ETFs with the largest weight of Enliven Therapeutics (NASDAQ:ELVN) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA). How do I buy shares of Enliven Therapeutics? Shares of ELVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ELVN) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
